E-ISSN: 2791-8823
Cam & Sakura Medical Journal
Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity [Cam Sakura Med J]
Cam Sakura Med J. 2022; 2(2): 49-58 | DOI: 10.4274/csmedj.galenos.2022.2022-1-4

Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity

Orhan Özdoğan1, Ali Ayçiçek2, Sibel Tekgündüz2, Ezgi Paslı Uysalol2, Müge Gökçe3, Cengiz Bayram2
1Hacettepe University Faculty of Medicine, Department of Pediatric Neurology, Ankara, Turkey
2University of Health Sciences Turkey, Başakşehir Çam and Sakura City Hospital, Clinic of Pediatric Hematology Oncology, İstanbul, Turkey
3Memorial Bahçelievler Hospital, Clinic of Pediatric Hematology Oncology, İstanbul, Turkey

Objective: The study aimed to evaluate the acute toxicity, overall survival (OS) and event-free survival (EFS) of children with acute lymphoblastic leukemia (ALL).
Material and Methods: This study included retrospective analysis of the medical records of 129 pediatric ALL patients aged 1 to 18 years old. Gender, risk group, central nervous system involvement at diagnosis, relapse and mortality status of patients, OS and EFS was evaluated. The Kaplan-Meier method was used to estimate survival rates. The survival difference of two groups was compared using the log-rank test.
Results: Eighty-six (66%) patients were boys and forty-three (33%) were girls. The mean age at diagnosis was 6.9±4.46 and 5.6±4.01 in male and female, respectively. Seventeen (13%) patients were classified as standard risk, 76 (58%) were intermediate risk, and 36 (27%) were high risk. Three patients (2.3%) died from acute toxicity during induction therapy. The median duration of follow-up was 25 months (range 1-65 months). The estimated 5-year OS and EFS was 88±4.6% and 78±4.1%, respectively. The estimated 5-year OS for the standard, intermediate and high-risk groups were 94±5.7%, 93±3.1%, and 59±13%, respectively, and EFS was 94±5.7%, 86.6±4.2%, and 49.9±10%, respectively.
Conclusion: The OS and EFS for standard-risk and intermediate-risk groups were good and comparable to the literature. However, the current study’s results should be confirmed in a larger patient population and a longer follow-up period.

Keywords: Children, acute lymphoblastic leukemia, event-free survival, overall survival

Orhan Özdoğan, Ali Ayçiçek, Sibel Tekgündüz, Ezgi Paslı Uysalol, Müge Gökçe, Cengiz Bayram. Overall and Event-free Survival in Children with Acute Lymphoblastic Leukemia and Evaluation of Treatment Related Acute Toxicity. Cam Sakura Med J. 2022; 2(2): 49-58

Corresponding Author: Ali Ayçiçek, Türkiye
Manuscript Language: English
LookUs & Online Makale